Author

R. Pajon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

H. Tang· 2 shared X. Shen· 2 shared A. Carfi· 1 shared A. Choi· 1 shared A. Jassem· 1 shared A. Netzl· 1 shared B. F. Haynes· 1 shared B. Korber· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

H. Tang

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mapping SARS-CoV-2 antigenic relationships and serological responses

S. H. Wilks, B. Muhlemann, X. Shen, S. Tureli, E. B. LeGresley, A. Netzl, M. A. Caniza, J. N. Chacaltana-Huarcaya, V. M. Corman, X. Daniell, M. B. Datto, F. S. Dawood, T. N. Denny, C. Drosten, R. A. M. Fouchier, , D. J. Smith

The paper uses antigenic cartography to analyze cross-reactivity among SARS-CoV-2 variants and human sera, identifying amino acid substitutions and immunodominance patterns affecting immune escape and vaccine efficacy.

bioRxiv · Jan 28, 2022Immunology

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants

A. Choi, M. Koch, K. Wu, G. Dixon, J. Oestreicher, H. Legault, G. B. E. Stewart-Jones, T. Colpitts, R. Pajon, H. Bennett, A. Carfi, D. K. Edwards

This study evaluates the neutralizing activity of mRNA-1273 vaccine-induced sera against SARS-CoV-2 variants, finding reduced but still effective neutralization against several variants compared to the wild-type virus.

bioRxiv · Jun 28, 2021Microbiology

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines

X. Shen, H. Tang, C. McDana, K. Wagh, W. Fischer, J. Theiler, H. Yoon, D. Li, B. F. Haynes, K. O. Saunders, S. Gnanakaran, N. W. Hengartner, R. Pajon, G. Smith, F. Dubovsky, , D. Montefiori

This study shows that B.1.1.7 SARS-CoV-2 variant remains neutralizable by antibodies from ancestral Spike vaccines and convalescent sera, though with reduced efficacy.

bioRxiv · Jan 27, 2021Immunology